SCHEMBL1102535

SCHEMBL1102535

c1ccc2c(-c3ccc4c5c(cccc35)CC4)c3cnccc3c(-c3ccc4c5c(cccc35)CC4)c2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 5/20 0.60
CYP11B2 P19099 5/20 0.60
ALDH1A1 P00352 4/20 0.41
HPGD P15428 4/20 0.41
KDM4E B2RXH2 4/20 0.41
LMNA P02545 3/20 0.41
MEN1 O00255 2/20 0.41
GAA P10253 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPT P10636 2/20 0.41
POLB P06746 1/20 0.39
ATM Q13315 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 2/20 0.36
CYP3A4 P08684 2/20 0.36
ALOX15 P16050 1/20 0.36
CDK4 P11802 1/20 0.35
CCND1 P24385 1/20 0.35
CYP19A1 P11511 3/20 0.34
TNF P01375 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1102670 0.93 CYP11B1 (0.60) CYP11B1CYP11B2ALDH1A1HPGDKDM4E
SCHEMBL1102491 0.81 CRHBP (0.43) CYP11B1CYP11B2ALDH1A1HPGDKDM4E
SCHEMBL12887230 0.80 CYP11B1 (0.40) CYP11B1CYP11B2ALDH1A1HPGDKDM4E
SCHEMBL12886859 0.80 CYP11B1 (0.40) CYP11B1CYP11B2ALDH1A1HPGDKDM4E
SCHEMBL1102881 0.78 CYP11B2 (0.51) CYP11B1CYP11B2ALDH1A1HPGDKDM4E
SCHEMBL1102487 0.77 TNF (0.41) CYP11B1CYP11B2ALDH1A1HPGDKDM4E
SCHEMBL1102905 0.76 TNF (0.47) CYP11B2ALDH1A1HPGDKDM4ELMNA
SCHEMBL1102907 0.76 TNF (0.54) CYP11B2ALDH1A1HPGDKDM4ELMNA
SCHEMBL1103279 0.75 CYP11B2 (0.46) CYP11B1CYP11B2ALDH1A1HPGDKDM4E
SCHEMBL12887313 0.75 CYP11B1 (0.39) CYP11B1CYP11B2KDM4EPOLBCYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
EP-2147962-A1 Azaanthracene-derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 CYP11B1 836/4885CYP11B2 652/4885ALDH1A1 1015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.